Satisfy: A Eurobloodnet Multicenter, Single-Arm Phase 2 Trial of Mitapivat in Adult Patients with Erythrocyte Membranopathies and Congenital Dyserythropoietic Anemia Type II - Results from the 8-Week Dose-Escalation Period
Thomas Doeven(Utrecht University), Andreas Glenthøj(University of Copenhagen), Fatiha Chermat(Groupe Francophone des Myélodysplasies), Niels Vejlstrup(Copenhagen University Hospital), Minke A.E. Rab(Utrecht University), Jesper Petersen(Copenhagen University Hospital), Kevin H.M. Kuo(University Health Network), Richard van Wijk(Utrecht University), Jonathan R.A. de Wilde(Utrecht University), Jens Helby(University of Copenhagen), Selma Kofoed Bendtsen(Copenhagen University Hospital), Pierre Fenaux(Université Paris Cité), Evelyn Groot(University Medical Center Utrecht), Jennifer Bos(Utrecht University), Eduard J. van Beers(Utrecht University), Adeline Gladieux, Joline L. Saes(Utrecht University)
Cited by 2
Related Papers
The energy-less red blood cell is lost: erythrocyte enzyme abnormalities of glycolysis
|Blood|2005|366
A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia
|New England Journal of Medicine|2020|320
Clinical spectrum of pyruvate kinase deficiency: data from the Pyruvate Kinase Deficiency Natural History Study
|Blood|2018|165
Safety and Efficacy of Mitapivat in Pyruvate Kinase Deficiency
|New England Journal of Medicine|2019|162